HD-OPM Archive
Topics › GLP-1 drugs (semaglutide, tirzepatide)

GLP-1 drugs linked to lower risk of knee replacement in knee osteoarthritis

Louis Nervegna · Jun 15, 2026 · ♥ 6 reactions · 2 comments · original Facebook post
GLP-1 drugs (semaglutide, tirzepatide)Weight, visceral & liver fat
AI summary & key facts

A shared Discover Magazine report says a records-based study found people with knee osteoarthritis taking GLP-1 receptor agonists had a significantly lower long-term risk of knee replacement, strongest with semaglutide and tirzepatide and with longer treatment. Louis added only hashtags; this is observational data.

#glp1HD #arthritisHD #kneeHD #kneereplacementHD

GLP-1 drugs like Ozempic and Mounjaro may do more than help people lose weight — they could also lower the chances of needing knee replacement surgery.

A new study found that people with knee osteoarthritis who took GLP-1 receptor agonists had a significantly lower long-term risk of undergoing knee replacement compared with similar patients who did not take the drugs. The strongest benefits were seen with newer medications such as semaglutide and tirzepatide and among people who stayed on treatment for longer periods.

Researchers analyzed medical records from tens of thousands of patients and found that the protective effect grew over time.

Scientists think the drugs may help not only through weight loss, but also by reducing inflammation and potentially protecting joint cartilage from further damage. However, the study was observational and cannot prove that the medications directly prevented surgery.

No photo description available.
← newer: Psyllium lowers LDL 13 mg/dL and fasting glucose 37 mg/dL inolder: Magnesium L-threonate for 6 weeks improved cognitive age ~7. →